| scholarly article | Q13442814 |
| P356 | DOI | 10.2967/JNUMED.108.058487 |
| P698 | PubMed publication ID | 19289418 |
| P50 | author | Karen Alt | Q61013891 |
| Philipp Wolf | Q61089862 | ||
| P2093 | author name string | John Shively | |
| Bernd J Pichler | |||
| Gerald Reischl | |||
| Patrick Bühler | |||
| Ursula Elsässer-Beile | |||
| Hans-Jürgen Machulla | |||
| Martin S Judenhofer | |||
| Stefan Wiehr | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| prostate cancer | Q181257 | ||
| xenograft | Q64148587 | ||
| P304 | page(s) | 606-611 | |
| P577 | publication date | 2009-03-16 | |
| P1433 | published in | The Journal of Nuclear Medicine | Q7743608 |
| P1476 | title | PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen | |
| P478 | volume | 50 |
| Q33792596 | 'Image and treat': an individualized approach to urological tumors |
| Q39449818 | 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer |
| Q93083334 | 2-Aminoadipic Acid-C(O)-Glutamate Based Prostate-Specific Membrane Antigen Ligands for Potential Use as Theranostics |
| Q41600550 | A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer |
| Q37172093 | A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. |
| Q36339722 | Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology |
| Q57815798 | BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study) |
| Q37091554 | Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer |
| Q38962393 | Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model |
| Q39692454 | Comparison of bifunctional chelates for (64)Cu antibody imaging |
| Q98154721 | Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer |
| Q38744524 | Current use of PSMA-PET in prostate cancer management |
| Q36363280 | Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry |
| Q51664521 | Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models. |
| Q91595836 | Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen |
| Q36128629 | Functional imaging for prostate cancer: therapeutic implications |
| Q38397651 | Functional imaging for radiotherapy treatment planning: current status and future directions-a review |
| Q33827632 | GCPII imaging and cancer |
| Q37972920 | Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer |
| Q34152258 | Identification of an antibody fragment specific for androgen-dependent prostate cancer cells |
| Q36125199 | Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging |
| Q34509927 | ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo |
| Q90581932 | ImmunoPET: Concept, Design, and Applications |
| Q26824070 | Mapping biological behaviors by application of longer-lived positron emitting radionuclides |
| Q37719273 | Modalities for imaging of prostate cancer |
| Q90026625 | Molecular Imaging of a Zirconium-89 Labeled Antibody Targeting Plasmodium falciparum-Infected Human Erythrocytes |
| Q36129937 | Molecular imaging of prostate cancer: PET radiotracers |
| Q30474579 | Molecular imaging: current status and emerging strategies |
| Q35911784 | New agents and techniques for imaging prostate cancer |
| Q43177005 | PSMA as a target for radiolabelled small molecules |
| Q39017235 | Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody. |
| Q42429164 | Positive progress in immunoPET--not just a coincidence |
| Q36557471 | Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments |
| Q37108209 | Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancer |
| Q39028837 | Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA). |
| Q52982515 | Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor. |
| Q27013843 | Prostate cancer relevant antigens and enzymes for targeted drug delivery |
| Q36135685 | Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. |
| Q36160805 | Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates |
| Q38015617 | Prostate-specific membrane antigen-based imaging |
| Q37656266 | Putative molecular signatures for the imaging of prostate cancer |
| Q39018543 | Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro |
| Q34196254 | Radioimmunoimaging of liver metastases with PET using a 64Cu-labeled CEA antibody in transgenic mice |
| Q37310963 | Serially heterotransplanted human prostate tumours as an experimental model |
| Q39070519 | Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer |
| Q34038524 | Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen |
| Q39417962 | Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment |
| Q38637803 | The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers. |
| Q37869905 | The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86. |
| Q37244969 | Translational Molecular Imaging of Prostate Cancer |
| Q38705627 | ⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer |
Search more.